Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors (PTK787)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00590343 |
Recruitment Status
:
Completed
First Posted
: January 10, 2008
Last Update Posted
: June 29, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Neuroendocrine Tumors | Drug: vatalanib | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label Phase II Study Evaluating the Safety and Efficacy of PTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors That Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms. |
Study Start Date : | November 2004 |
Actual Primary Completion Date : | March 2010 |
Actual Study Completion Date : | October 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
Intervention=Patients will receive treatment with PTK787/ZK222584 daily. A treatment cycle will be defined as a 28-day period. Subjects will continue on their present treatment regimen of receiving Sandostatin LAR 30mg IM every 4 weeks.
|
Drug: vatalanib
Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
|
- Change in biochemical markers. [ Time Frame: Quarterly= every 3 months ]
- Tumor response per triphasic CT scan. [ Time Frame: Quarterly= every 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Biopsy-proven metastatic neuroendocrine tumors (which extent is disease is determined by CT scan or MRI) and biochemical evidence of disease.
- Evidence of progressive disease or inadequate controlled disease related syndrome symptoms.
- Must be receiving Sandostatin LAR 30mg every 4 weeks
- Age >or= to 18 years old
- Karnofsky Performance Status > or = 60
- Measurable lesion(s) as per the modified RECIST criteria
- Laboratory values <or= 2 weeks prior to randomization: ANC >or= 1.5 x 10(9)/L, Platelets >or= 100 x 10 (9), Hemoglobin >or= 9g/dL, Serum creatinine <or= 1.5 ULN, Serum bilirubin <or= 1.5 ULN, Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) <or= 3.0 x ULN (<or= 5 x ULN if liver metastases present), Negative for proteinuria based on dip stick reading OR documentation of 1+ result for protein on dip stick reading, then total urinary protein <or= 500mg and measured creatinine clearance >or= 50ml/min from a 24 hour urine collection.
- Life expectancy >or= 12 weeks.
- Written informed consent obtained according to local guidelines.
Exclusion Criteria:
- Had previous radiolabeled somatostatin analog therapy within the last 6 months.
- Hepatic artery embolization within the last 6 months (1 month if there are other sites of measurable disease)
- Undergone cryoablation of hepatic metastasis within the last 2 months.
- History or presence of central nervous system (CNS) disease (ie:primary brain tumor, malignant seizures, CNS metastases or carcinomatous meningitis)
- History of another primary malignancy <or= 5 years, with the exception of inactive basal or squamous cell carcinoma of the skin.
- Prior chemotherapy <or= 3 weeks prior to registration and/or randomization. Patients must have recovered from all therapy-related toxicities.
- Prior biologic or immunotherapy <or= 2 weeks prior to registration and/or randomization. Patients must have recovered from all therapy-related toxicities.
- Prior full field radiotherapy <or= 4 weeks or limited field radiotherapy <or= 2 weeks prior to randomization. Patients must have recovered from all therapy-related toxicities. The site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease.
- Major surgery (ie:laparotomy) <or= 4 weeks prior to randomization. Minor surgery <or= 2 weeks prior to randomization. Insertion of a vascular access device is not considered major or minor surgery in this regard. Patients must have recovered from all surgery-related toxicities.
- Patients who have received investigational drugs <or= 4 weeks prior to registration.
- Prior therapy with anti-VEGF agents
- Pleural effusion or ascites that causes respiratory compromise (>or= CTC grade 2 dyspnea)
- Female patients who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, therefore not considered effective for this study. Women of childbearing potential must have a negative serum pregnancy test 48 hours prior to administration of study treatment.
- Uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen.
- Unstable angina pectoris
- Symptomatic congestive heart failure
- Myocardial infarction <or= 6 months prior to registration
- Active or uncontrolled infection
- Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
- Chronic renal disease
- Subjects at risk of significant cardiac arrythmias
- Uncontrolled diabetes
- Acute or chronic liver disease (eg:hepatitis, cirrhosis)
- Impairment of gastrointestinal function or GI disease that may significantly alter absorption (ie:ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the tablets.)
- Confirmed diagnosis of human immunodeficiency syndrome (HIV) infection are excluded at the investigator's discretion.
- Patients taking therapeutic warfarin sodium (Coumadin) or similar oral anticoagulants that are metabolized by the cytochrome P450 system. Heparin is allowed.
- Patients unwilling or unable to comply with the protocol.
- Known symptomatic gallstones
- Received glucocorticoid therapy within the past 6 months, or who are currently receiving any chemotherapeutic agents, insulin sensitizers (eg:metformin, pioglitazone, rosiglitazone), or exogenous growth hormones.
- Subjects with unacceptable concomitant diagnoses, or who have received medication and/or therapies (ie:illness or therapies that would place patient at increased risk, or would, in the opinion of the investigator, interfere with the evaluation of efficacy or safety.)
- Exhibit symptoms indicative of intolerance of Sandostatin LAR.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00590343
United States, Louisiana | |
Neuroendocrine Clinic | |
Kenner, Louisiana, United States, 70065 |
Principal Investigator: | Lowell B Anthony, MD | Lousiana State University Health Sciences Center-NO |
Publications:
Responsible Party: | Lowell Anthony, MD, Louisiana State University Health Sciences Center-New Orleans |
ClinicalTrials.gov Identifier: | NCT00590343 History of Changes |
Obsolete Identifiers: | NCT00627198 |
Other Study ID Numbers: |
PTK787/ZK222584 LSU IRB-6355 |
First Posted: | January 10, 2008 Key Record Dates |
Last Update Posted: | June 29, 2011 |
Last Verified: | June 2011 |
Additional relevant MeSH terms:
Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Nerve Tissue Vatalanib Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |